{"id":750437,"date":"2023-04-24T16:04:14","date_gmt":"2023-04-24T20:04:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\/"},"modified":"2023-04-24T16:04:14","modified_gmt":"2023-04-24T20:04:14","slug":"janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\/","title":{"rendered":"Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences<\/b><\/p>\n<p>SAN DIEGO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.januxrx.com%2F&amp;esheet=53386717&amp;newsitemid=20230424005872&amp;lan=en-US&amp;anchor=Janux+Therapeutics%2C+Inc.&amp;index=1&amp;md5=f6ca32438000193e9144295fa1bfbd18\">Janux Therapeutics, Inc.<\/a> (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate at two upcoming investor conferences and be available for 1&#215;1 meetings. Details of the conferences are as follows:<\/p>\n<p><b>H.C. Wainwright BioConnect Investor Conference at NASDAQ<br \/>\n<br \/><\/b>Date: Tuesday, May 2<br \/>\n<br \/>Time: 8am to 5pm ET<br \/>\n<br \/>Forum: 1&#215;1 meetings<br \/>\n<br \/>Location: NASDAQ World Headquarters, New York, NY<\/p>\n<p><b>BofA Securities 2023 Health Care Conference<br \/>\n<br \/><\/b>Dates: Tuesday, May 9 to Thursday, May 11<br \/>\n<br \/>Forum: 1&#215;1 meetings and corporate presentation<br \/>\n<br \/>Presentation Time: Wednesday, May 10 at 5pm PT<br \/>\n<br \/>Location: Encore Hotel, Las Vegas, NV<\/p>\n<p><b>Janux\u2019s TRACTr and TRACIr Pipeline<\/b><\/p>\n<p>\nJANX008 is a TRACTr that targets EGFR and is being studied in a Phase 1 clinical trial for the treatment of multiple solid cancers including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Janux\u2019s first clinical candidate, JANX007, is a TRACTr that targets PSMA and is being investigated in a Phase 1 clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). Janux\u2019s TRACIr drug candidate, JANX009, is designed for targeting both the programmed death-ligand 1 (PD-L1) receptor as well as the costimulatory CD28 receptor on T cells and is being investigated in preclinical studies for the treatment of solid tumors. Janux is also applying its proprietary technology to develop a TRACTr designed to target TROP2, a clinically validated anti-tumor target that is overexpressed in various cancer types, such as breast, lung, urothelial, endometrial, ovarian, prostate, pancreatic, gastric, colon, head and neck, and glioma. In addition to named programs, Janux is generating a number of unnamed TRACTr and TRACIr programs for potential future development.<\/p>\n<p><b>About Janux Therapeutics<\/b><\/p>\n<p>\nJanux is a clinical-stage biopharmaceutical company developing next-generation bispecific immunotherapies with the goal of fighting cancers by killing tumor cells while allowing healthy tissues to remain unharmed. Janux\u2019s proprietary platforms develop unique Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) and support the building of a broad pipeline of drugs designed to direct and guide the patient\u2019s immune system to eradicate tumors while minimizing safety concerns. The company&#8217;s innovative technology currently focuses on the engineering of bispecific antibodies functional only in the tumor, providing safety advantages compared to earlier generations of bispecific immunotherapies. Currently, Janux\u2019s two lead TRACTr compounds for PSMA and EGFR are in the clinic. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.januxrx.com&amp;esheet=53386717&amp;newsitemid=20230424005872&amp;lan=en-US&amp;anchor=www.januxrx.com&amp;index=2&amp;md5=59d2d68f09a2de800c01e865904857de\">www.januxrx.com<\/a> and follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fjanux-therapeutics&amp;esheet=53386717&amp;newsitemid=20230424005872&amp;lan=en-US&amp;anchor=LinkedIn.&amp;index=3&amp;md5=acd5ed83b9f4a09e7488f7510bc8a563\">LinkedIn.<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230424005872r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230424005872\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230424005872\/en\/<\/a><\/span><\/p>\n<p><b>Investors:<br \/>\n<\/b><br \/>Andy Meyer<br \/>\n<br \/>Janux Therapeutics<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ameyer@januxrx.com\">ameyer@januxrx.com<br \/>\n<\/a><br \/>(202) 215-2579<\/p>\n<p><b>Media:<br \/>\n<\/b><br \/>Jessica Yingling, Ph.D.<br \/>\n<br \/>Little Dog Communications Inc.<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jessica@litldog.com\">jessica@litldog.com<br \/>\n<\/a><br \/>(858) 344-8091<\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Science Other Science Biotechnology Research Pharmaceutical Oncology Health Other Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230424005872\/en\/1772598\/3\/Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate at two upcoming investor conferences and be available for 1&#215;1 meetings. Details of the conferences are as follows: H.C. Wainwright BioConnect Investor Conference at NASDAQ Date: Tuesday, May 2 Time: 8am to 5pm ET Forum: 1&#215;1 meetings Location: NASDAQ World Headquarters, New York, NY BofA Securities 2023 Health Care Conference Dates: Tuesday, May 9 to Thursday, May 11 Forum: 1&#215;1 meetings and corporate presentation Presentation &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-750437","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate at two upcoming investor conferences and be available for 1&#215;1 meetings. Details of the conferences are as follows: H.C. Wainwright BioConnect Investor Conference at NASDAQ Date: Tuesday, May 2 Time: 8am to 5pm ET Forum: 1&#215;1 meetings Location: NASDAQ World Headquarters, New York, NY BofA Securities 2023 Health Care Conference Dates: Tuesday, May 9 to Thursday, May 11 Forum: 1&#215;1 meetings and corporate presentation Presentation &hellip; Continue reading &quot;Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-24T20:04:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230424005872r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences\",\"datePublished\":\"2023-04-24T20:04:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\\\/\"},\"wordCount\":503,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230424005872r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\\\/\",\"name\":\"Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230424005872r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-04-24T20:04:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230424005872r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230424005872r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences - Market Newsdesk","og_description":"Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate at two upcoming investor conferences and be available for 1&#215;1 meetings. Details of the conferences are as follows: H.C. Wainwright BioConnect Investor Conference at NASDAQ Date: Tuesday, May 2 Time: 8am to 5pm ET Forum: 1&#215;1 meetings Location: NASDAQ World Headquarters, New York, NY BofA Securities 2023 Health Care Conference Dates: Tuesday, May 9 to Thursday, May 11 Forum: 1&#215;1 meetings and corporate presentation Presentation &hellip; Continue reading \"Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-24T20:04:14+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230424005872r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences","datePublished":"2023-04-24T20:04:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\/"},"wordCount":503,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230424005872r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\/","name":"Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230424005872r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-04-24T20:04:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230424005872r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230424005872r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/janux-therapeutics-to-participate-at-upcoming-may-2023-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/750437","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=750437"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/750437\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=750437"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=750437"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=750437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}